TABLE 2.
Base case treatment consequences
| End point | Linezolid group | Vancomycin IV group |
|---|---|---|
| Length of stay (days) | ||
| Median† (95% CI) | 16.0 (11-21) | 17.0 (15-25) |
| Mean† (SE) | 21.4 (1.8) | 23.4 (1.7) |
| % discharged by: | ||
| Day 7 | 29.2 | 20.2 |
| Day 14 | 42.7 | 34.8 |
| Day 21 | 60.7 | 56.2 |
| Day 28 | 67.4 | 66.3 |
| Day 56 | 86.5 | 86.5 |
| Duration of treatment (days) | ||
| IV only | ||
| Mean (SE) | 12.3 (1.9)* | 19.7 (2.1)* |
| Median | 7.0** | 14.0** |
| IV and oral | ||
| Mean (SE) | 21.1 (2.2) | 20.8 (2.2) |
| Median | 15.5 | 16.0 |
‡
Estimated using Kaplan-Meier survival function
*
P=0.01;
**
P=0.0002. IV Intravenous